公司股东户数为2.35万户，前十大股东持股数量为1.02亿股，占总股本比例为50.18%，前十大股东持股 情况如下： | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | J | 武汉统盛投资有限公司 | 40.92% | | 2 | 梁栋国 | 5.18% | | 3 王铁 | 姚寅之 | 1.13% 0.55% | | રે | 武汉回盛生物科技股份有限公司-2023年员工持股计划 | 0.49% | | 壬萌 6 | | 0.43% | | 7 | 平安资管-工商银行-鑫福37号资产管理产品 | 0.40% | | 8 | 中汇人寿保险股份有限公司-分红产品 | 0.40% | | 9 | UBS AG | 0.38% | | 10 | 谭绮辉 | 0.32% | 2025年8月6日，回盛生物(300871.SZ)发布2025年中报。 公司营业总收入为8.22亿元。归母净利润为1.17亿元。经营活动现金净流入为1.24亿元。 公司最新资产负债率为30.41%。 公司最新毛利率为27.56%。最新ROE为5.69%。 公司摊薄每股收益为0.66元。 公司最新总资产周转率为0 ...

Group 1 - The company has approved a profit distribution plan, proposing a cash dividend of 1.00 yuan per 10 shares (including tax) to all shareholders, with no bonus shares issued and no capital reserve conversion into shares [1] - The total share capital for the dividend distribution is based on 201,578,957 shares after excluding 753,600 shares held in the repurchase special securities account [1] - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period [3] Group 2 - There are no preferred shareholders or changes in preferred shareholder holdings during the reporting period [3] - The company does not require retrospective adjustments or restatements of previous accounting data [2] - The company has not experienced any changes in the number of shareholders or significant shareholders during the reporting period [2]

Core Viewpoint - Wuhan Huasen Biological Technology Co., Ltd. reported significant growth in revenue and profit for the first half of 2025, indicating a strong operational performance compared to the previous year [1][2]. Financial Performance - The company's operating revenue reached approximately 822.20 million yuan, an increase of 88.45% compared to 436.30 million yuan in the same period last year [1]. - Net profit attributable to shareholders was approximately 117.18 million yuan, reflecting a substantial increase of 325.88% from a loss of 51.88 million yuan in the previous year [1]. - The net cash flow from operating activities was approximately 123.85 million yuan, showing a remarkable increase of 499.41% compared to a decrease of 31.01 million yuan in the previous year [1]. - Basic and diluted earnings per share were both 0.6622 yuan, marking an increase of 311.77% from a loss of 0.3127 yuan per share in the previous year [1]. Asset and Equity Position - Total assets at the end of the reporting period were approximately 2.97 billion yuan, a decrease of 1.55% from 3.01 billion yuan [2]. - Net assets attributable to shareholders increased by 41.23% to approximately 2.06 billion yuan from 1.46 billion yuan [2]. Shareholder Information - The largest shareholder, Wuhan Tongseng Investment Co., Ltd., holds 40.92% of the shares, with a total of 82.80 million shares [2]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [3].

Core Viewpoint - The company has proposed a cash dividend distribution plan for the first half of 2025, reflecting its profitability and commitment to shareholder returns [1][2][3]. Profit Distribution Plan - As of June 30, 2025, the company reported a net profit attributable to shareholders of 117,181,542.91 yuan, resulting in a total distributable profit of 372,964,159.44 yuan after accounting for previous distributions [1]. - The proposed cash dividend is 1.00 yuan per 10 shares, totaling 20,157,895.70 yuan, which represents 17.20% of the net profit for the first half of 2025 [2][3]. - The total number of shares for the dividend calculation is based on 201,578,957 shares after excluding treasury shares [2]. Approval Process and Legitimacy - The dividend proposal has been authorized by the 2024 annual general meeting, allowing the board to decide on the mid-year dividend based on actual conditions [2]. - The distribution plan complies with relevant regulations and the company's articles of association, ensuring its legality and reasonableness [3]. Additional Information - The company has taken measures to prevent insider trading and ensure confidentiality regarding the dividend proposal [3]. - The proposed distribution is designed to balance shareholder returns with the company's operational needs and long-term development [3].

Group 1 - The board of directors of Wuhan Huirong Biological Technology Co., Ltd. held its 23rd meeting on August 5, 2025, with all five directors present, and the meeting complied with relevant laws and regulations [1] - The board unanimously approved the 2025 semi-annual report, confirming that it accurately reflects the company's operational status without any false statements or omissions [2][3] - The board approved the special report on the use of raised funds, ensuring compliance with relevant regulations and confirming no violations in the management and disclosure of raised funds [2][3] Group 2 - The board proposed a profit distribution plan for the first half of 2025, recommending a cash dividend of 20,157,895.70 yuan (before tax) based on a total share capital of 202,332,557 shares as of June 30, 2025 [2][3] - The profit distribution plan does not require shareholder meeting approval as it was authorized in the 2024 annual shareholder meeting [3] - The board approved the appointment of Han Jie as the rotating general manager, with the term lasting until the end of the current board's term [4] Group 3 - The board approved an investment of 170 million yuan in a project to upgrade veterinary raw material production equipment, aimed at enhancing product quality and increasing production capacity [5] - The company plans to change its registered capital from 179,194,432 yuan to 202,332,557 yuan due to the conversion of convertible bonds into shares, and to relocate its registered address [6] - The board agreed to convene the second extraordinary general meeting of shareholders on August 22, 2025 [6]

Meeting Overview - The third supervisory board meeting of Wuhan Huaneng Biological Technology Co., Ltd. was held on August 5, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Resolutions Passed - The supervisory board approved the "2025 Half-Year Report" and its summary, confirming that the report accurately reflects the company's situation without any misleading statements or omissions [1][2]. - The board also approved the "Special Report on the Storage and Use of Raised Funds for the First Half of 2025," affirming compliance with regulations regarding the management and disclosure of raised funds [2][3]. - The "Profit Distribution Plan for the First Half of 2025" was approved, ensuring it considers the company's profitability and cash flow without harming minority shareholders' interests [2][3]. - The board approved the investment in a green equipment technological transformation project for veterinary raw materials, aimed at enhancing production capacity and product quality [3].

证券代码：300871 证券简称：回盛生物 公告编号：2025-077 武汉回盛生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 5 日召开第三届董事会第二十三次会议，审议通过了《关于提请召开公司 2025 年第二次临时股东大会的议案》，并定于 2025 年 8 月 22 日（星期五）14:00 召开 2025 年第二次临时股东大会。现将本次股东大会的相关事项通知如下： 一、召开会议的基本情况 行政法规、部门规章、规范性文件、深圳证券交易所（以下简称"深交所"） 业务规则和《公司章程》等规定。 （1）现场会议召开时间：2025 年 8 月 22 日（星期五）14:00； （2）网络投票时间：2025 年 8 月 22 日，其中，通过深交所交易系统进 行网络投票的具体时间为 2025 年 8 月 22 日 9:15—9:25、9:30—11:30 和 13:00 通过深交所互联网投票系统投票的具体时间为 2025 年 8 月 22 日 9:15 —15:00； —15: ...

Core Viewpoint - The company, Kuaisheng Biological, announced a semi-annual distribution plan for 2025, proposing a cash dividend of 1 yuan per 10 shares, totaling approximately 20.16 million yuan, which represents 17.20% of its net profit, marking the sixth distribution since its listing [2]. Financial Performance - For the first half of 2025, the company reported revenue of 822 million yuan, reflecting a year-on-year increase of 88.45% - The net profit reached 117 million yuan, showing a significant year-on-year growth of 325.88% - Basic earnings per share were recorded at 0.6622 yuan, with a weighted average return on equity of 7.01% [2]. Market Activity - The stock experienced a net inflow of 36.11 million yuan from main funds today, with a total net inflow of 118 million yuan over the past five days [3]. - The latest margin financing balance for the stock is 224 million yuan, which has increased by 24.18 million yuan over the past five days, representing a growth rate of 12.11% [4]. Industry Comparison - In the agricultural, forestry, animal husbandry, and fishery sector, five companies have announced their semi-annual distribution plans for 2025 - Haida Group leads with a cash distribution of 333.27 million yuan, followed by Yisheng Co. and Zhongchong Co. with distributions of 162.78 million yuan and 60.87 million yuan, respectively [4][5].

Core Viewpoint - The company reported significant growth in revenue and net profit for the first half of 2025, indicating a recovery in the animal health sector after a period of decline [1][2]. Financial Performance - The company's revenue for the first half of 2025 was approximately 822 million yuan, an increase of 88.45% year-on-year [1]. - The net profit attributable to shareholders was about 117 million yuan, marking a turnaround from losses with a year-on-year growth of 325.88% [1]. - In Q1 2025, revenue grew by 92.96% and net profit increased by 371.23% [2]. Segment Analysis - Sales revenue from chemical drug formulations increased by 54.23% year-on-year, although the gross margin decreased by 0.36% [1]. - Sales revenue from veterinary raw materials surged by 199.01% year-on-year, with a gross margin improvement of 27.14% [1]. Investment and Expansion Plans - The company plans to invest 170 million yuan in upgrading its veterinary raw material production lines, which will enhance efficiency and reduce costs [2]. - The upgrade will include the introduction of high-efficiency, automated equipment and the addition of fermentation product production lines [2]. Strategic Focus - The company is focusing on vertical integration in the raw material drug industry and horizontal expansion into pet, poultry, ruminant, and aquaculture sectors [3]. - The strategy includes developing new veterinary drugs, optimizing product performance, and expanding into international markets to mitigate domestic cyclical impacts [3].

（文章来源：证券日报） 证券日报网讯 8月5日晚间，回盛生物发布公告称，公司第三届董事会第二十三次会议审议通过了《关 于及其摘要的议案》等多项议案。 ...